Loading
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Latest quote
$13.75
−$0.19 · -1.36%
After-hours
$13.70
−$0.05 · -0.36%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Day range
Current $13.75
52-week range
Current $13.75
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
44
Mixed
Risk
56
Elevated Risk
Momentum
56
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Day range
Current $13.75
52-week range
Current $13.75
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 120.79M USD | 17.2M USD | 5.9M USD | 7.5M USD | 10.21M USD |
| Cost of goods sold | 19.21M USD | 5.13M USD | 41.07M USD | 54.92M USD | 63.57M USD |
| Gross profit | 101.58M USD | 12.07M USD | −35.17M USD | −47.42M USD | −53.36M USD |
| Research and development | 97.94M USD | 34.81M USD | 25.35M USD | 27.19M USD | 32.82M USD |
| Selling, general, and administrative | 55.13M USD | 39.31M USD | 23.63M USD | 53.11M USD | 57.97M USD |
| Operating expenses | 153.08M USD | 74.51M USD | 48.98M USD | 76.79M USD | 90.79M USD |
| Interest income | 3.93M USD | 3.55M USD | 1.82M USD | 831K USD | — |
| Interest expense | 23.95M USD | 22.93M USD | 20.66M USD | 19.44M USD | 17.29M USD |
| Depreciation and amortization | 8.62M USD | 6.4M USD | 4.67M USD | 4.11M USD | 4.38M USD |
| Operating income | −51.5M USD | −62.44M USD | −84.15M USD | −69.29M USD | −80.57M USD |
| Net income | −57.76M USD | −102.14M USD | −87.96M USD | −81.89M USD | −91.35M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jan 10, 2024 | 1:2 | — | — |
Stock split | Dec 5, 2023 | 529:500 | — | — |
Stock split | Aug 29, 2017 | 1,011:1,000 | — | — |
Effective Jan 10, 2024
1:2
Effective Dec 5, 2023
529:500
Effective Aug 29, 2017
1,011:1,000
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB7.75M0.07%10.41B USD0.44%$200.48-1.41%
ActivePassive International Equity ETFAPIE160.05K0.01%1.17B USD0.45%$38.31-0.70%
Invesco NASDAQ Future Gen 200 ETFQQQS99.8K0.44%22.96M USD0.20%$41.5683-1.09%
Invesco Nasdaq Biotechnology ETFIBBQ54.7K0.05%109.17M USD0.19%$33.6249-1.13%
ProShares Ultra Nasdaq BiotechnologyBIB25.73K0.03%90.28M USD1.19%$105.02-2.27%iShares Biotechnology ETFIBBActivePassive International Equity ETFAPIEInvesco NASDAQ Future Gen 200 ETFQQQSInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
